The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy.
David A. Smith
Research Funding - EMD Serono
Paul Conkling
Research Funding - US Oncology
Donald A. Richards
No relevant relationships to disclose
Maria Regina C. Flores
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Thomas E. Boyd
No relevant relationships to disclose
Alain C. Mita
Honoraria - Roche/Genentech
Guillaume de La Bourdonnaye
Employment or Leadership Position - Merck KGaA
David Wages
Employment or Leadership Position - EMD Serono
Alice Susannah Bexon
Consultant or Advisory Role - Idera Pharmaceuticals